Denali at Cantor global healthcare conference: launch gains traction

Denali reported $3.6 million of second-quarter AVLAYAH revenue in its first commercial quarter and guided to $10 million-$12 million for Q3, implying substantial sequential launch growth driven by new patient starts and dose escalation. The company holds approximately $1.1 billion of cash, which management expects to fund operations through 2029, while estimating a $7 billion-$9 billion peak-sales opportunity across its enzyme-replacement portfolio. Key value catalysts include five clinical-stage data readouts in 2027, a planned 2027 BLA filing for Sanfilippo therapy Zafi, and mid-2028 COMPASS Phase III data needed to support broader AVLAYAH labeling and major European expansion; execution, manufacturing, and regulatory risks remain material.

Analysis

DNLI’s near-term equity sensitivity is not the headline launch ramp but the conversion of switches into durable, reimbursed patients after the clinic-based titration period. That creates a potentially misleading 3Q/4Q revenue cadence: revenue can rise rapidly on dose escalation while the true commercial KPI—net new treated patients, persistence through home infusion, and gross-to-net—remains unreported. The small prevalent pool also means a handful of delayed authorizations or discontinuations can materially alter quarterly growth and invite multiple volatility.

The principal competitive casualty is Takeda’s Elaprase franchise, but the more investable implication is that DNLI must demonstrate clinically motivated switching rather than temporary novelty. If AVLAYAH’s neurologic differentiation drives broad conversion, the franchise may support premium rare-disease economics; if milder patients resist the re-initiation burden, penetration likely plateaus well below management’s implied opportunity. Internal manufacturing is a longer-dated margin lever, but it is also a 2027 filing bottleneck: CMC validation failure or delay would impair both Sanfilippo timing and the platform’s claimed repeatability.

Consensus is likely assigning disproportionate value to the 2027 cluster of neurologic readouts while discounting that these programs share a platform and biomarker-regulatory thesis. That correlation cuts both ways: a credible NfL trajectory in FTD-GRN could re-rate the platform and reduce financing risk, whereas an unconvincing result would pressure not only that asset but the probability-weighting of Alzheimer’s and future CNS programs. Over the next 1-3 months, payer-policy expansion and patient-start disclosures matter more than conference commentary; over 6-18 months, manufacturing readiness and Sanfilippo filing quality become the key de-risking events.

Key Decisions for Investors

• Maintain DNLI as a catalyst watch/accumulate-on-confirmation rather than chase the launch narrative: add only if the next update discloses sustained net patient additions and reiterates revenue guidance after early titration cohorts transition to home infusion. Thesis fails if sequential revenue growth decelerates before meaningful Medicaid expansion or management flags elevated discontinuations/gross-to-net pressure.
• Use a defined-risk long DNLI position sized for binary biotech correlation, with a 6-12 month horizon into 2027 data and manufacturing milestones. Risk/reward improves materially if enterprise value approaches cash-adjusted levels; avoid underwriting the full enzyme-franchise peak-sales claim until Sanfilippo CMC readiness and pricing assumptions are independently evidenced.
• Monitor NVS as the relevant large-cap read-through rather than a direct pair-trade target: any evidence that AVLAYAH switching is durable creates downside risk to the incumbent Hunter enzyme franchise, but the asset is unlikely to be material enough to move NVS absent broader rare-disease portfolio implications.
• Set alerts for: quarterly AVLAYAH revenue below the guided trajectory; fewer new starts versus dose-escalation-driven revenue; delayed internal-facility validation; or a revised 2027 filing timeline. Any of these would challenge the operational execution thesis before the major clinical catalysts.